This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Nerve damage	Low-density lipoprotein-related protein 1 α -2-macroglobulin receptor (LRP1; CD91); neurotrophic tyrosine kinase receptor 3 (NTRK3; TrkC)	<p>Cell culture and rat studies suggest targeting LRP1 could promote neuronal regeneration. In rat dorsal root ganglion cultures, LRP1 agonists stimulated neurite outgrowth by activating TrkC signaling. In rats, intrathecal infusion of glutathione-S-transferase (GST) fusion proteins that agonize LRP1 increased TrkC pathway activity and neurite outgrowth compared with no GST infusion. In rat models of spinal cord injury, infusion of LRP1 ligands increased axonal projections and regeneration at lesion sites compared with vehicle. Next steps include testing and defining the effects of LRP1 ligands in additional injury models.</p> <p>Angiochem Inc's ANG2004, an LRP1-targeting peptide, is in preclinical development for diabetes and obesity. Raptor Pharmaceutical Corp's HepTide, an LRP1-targeting peptide, is in preclinical development for liver cancer.</p> <p>SciBX 6(33); doi:10.1038/scibx.2013.901 Published online Aug. 29, 2013</p>	Patent and licensing status unavailable	<p>Yoon, C. <i>et al. J. Biol. Chem.</i>; published online July 18, 2013; doi:10.1074/jbc.M113.478552</p> <p>Contact: W. Marie Campana, University of California, San Diego, La Jolla, Calif. e-mail: wcampana@ucsd.edu</p>